Provided by Tiger Trade Technology Pte. Ltd.

Agenus

6.94
+0.05000.73%
Post-market: 6.89-0.0500-0.72%19:55 EDT
Volume:790.46K
Turnover:5.43M
Market Cap:312.44M
PE:2.78
High:7.02
Open:6.93
Low:6.70
Close:6.89
52wk High:8.85
52wk Low:2.71
Shares:45.02M
Float Shares:42.21M
Volume Ratio:0.75
T/O Rate:1.87%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.50
EPS(LYR):-0.0034
ROE:-1278.83%
ROA:12.53%
PB:-1.57
PE(LYR):-2,043.58

Loading ...

Agenus Inc expected to post earnings of $2.10 a share - Earnings Preview

Reuters
·
May 08

Agenus to report first-quarter results before market open

Reuters
·
May 05

Agenus to Provide First Quarter 2026 Financial Report and Corporate Update

THOMSON REUTERS
·
May 05

Agenus to present first Phase 2 botensilimab melanoma data at ASCO 2026

Reuters
·
Apr 21

Agenus names BAP Pharma exclusive global partner for botensilimab-balstilimab access programs

Reuters
·
Apr 21

Agenus announces annual shareholder meeting webcast

Reuters
·
Apr 21

Agenus reports Phase 2 results from BOT and BAL with agenT-797

TIPRANKS
·
Apr 18

BRIEF-Agenus Reports Phase Ii Data Demonstrating Immune Reprogramming And Durable Survival With Botensilimab, Balstilimab And Agent-797 In Pd-1 Refractory Gastroesophageal Cancer

Reuters
·
Apr 18

Agenus reports Phase II data showing 77% disease control in PD-1 refractory gastroesophageal cancer

Reuters
·
Apr 18

Agenus Inc - Study Does Not Meet Primary Endpoint of Objective Response Rate

THOMSON REUTERS
·
Apr 18

Agenus to present Phase II BOT+BAL plus agenT-797 data in PD-1 refractory GEC at AACR

Reuters
·
Apr 03

Agenus Announces Data From Phase Ii Study of BOT+Bal in Combination With Agent-797 in Pd-1 Refractory Gastroesophageal Cancer to Be Presented at Aacr 2026

THOMSON REUTERS
·
Apr 03

Agenus Says First Patient Enrolled in Phase 3 Colorectal Cancer Trial

MT Newswires Live
·
Apr 01

Agenus enrolls first patient in Phase 3 BATTMAN trial for BOT+BAL in MSS mCRC

Reuters
·
Apr 01

Agenus Announces First Patient Enrolled in Global Phase 3 Battman Trial of BOT+Bal Immunotherapy Combination in Mss or Pmmr Metastatic Colorectal Cancer

THOMSON REUTERS
·
Apr 01

Agenus: Strengthening Bot/Bal Clinical Profile and Capital-Efficient Path to Registration Underpin Positive Rating

TIPRANKS
·
Apr 01

Agenus to host stakeholder webcast on BOT+BAL immunotherapy program; Q&A to follow live session

Reuters
·
Mar 27

Agenus securities class action dismissed in full; Massachusetts federal court denies leave to amend

Reuters
·
Mar 26

Mink Therapeutics names Melissa Orilall principal financial officer and Austin Charette principal accounting officer

Reuters
·
Mar 20

Agenus (AGEN) Q3 Profit Of US$63.9 Million Tests Longstanding Loss-Making Narrative

Simply Wall St.
·
Mar 18